O

OmniAb Inc
NASDAQ:OABI

Watchlist Manager
OmniAb Inc
NASDAQ:OABI
Watchlist
Price: 3.92 USD 1.82% Market Closed
Market Cap: 463.2m USD
Have any thoughts about
OmniAb Inc?
Write Note

OmniAb Inc
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

OmniAb Inc
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
O
OmniAb Inc
NASDAQ:OABI
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Danaher Corp
NYSE:DHR
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Agilent Technologies Inc
NYSE:A
Short-Term Debt
$795m
CAGR 3-Years
83%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

OmniAb Inc
Glance View

Market Cap
471.3m USD
Industry
Life Sciences Tools & Services

OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 93 full-time employees. The company went IPO on 2020-10-09. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. Its OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach and OmniTaur features structural attributes of cow antibodies for complex targets. The firm's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic targets.

OABI Intrinsic Value
4.35 USD
Undervaluation 10%
Intrinsic Value
Price
O

See Also

What is OmniAb Inc's Short-Term Debt?
Short-Term Debt
0 USD

Based on the financial report for Dec 31, 2023, OmniAb Inc's Short-Term Debt amounts to 0 USD.

Back to Top